Comparative Pharmacology
Head-to-head clinical analysis: AQUATENSEN versus MODURETIC 5 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUATENSEN versus MODURETIC 5 50.
AQUATENSEN vs MODURETIC 5-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AQUATENSEN (methylclothiazide) is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule of the nephron, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and blood pressure.
Combination diuretic: amiloride blocks epithelial sodium channels (ENaC) in distal tubule, inhibiting sodium reabsorption and potassium excretion; hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, increasing sodium, chloride, and water excretion.
1-2 mg orally once daily, titrated to blood pressure response; maximum dose 4 mg/day.
1 tablet (5 mg amiloride/50 mg hydrochlorothiazide) orally once daily, increased if needed to 2 tablets daily as a single dose or divided doses.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours (mean 10 h); clinically, allows twice-daily dosing
HCTZ: 5.6-14.8 hours; amiloride: 6-9 hours. Both prolonged in renal impairment (e.g., creatinine clearance <30 mL/min). Terminal elimination half-life for HCTZ may extend to >20 hours in severe renal disease.
Renal: 50% unchanged; Fecal: 20% (via bile); remainder as inactive metabolites
Both components are primarily excreted renally: hydrochlorothiazide (HCTZ) ~70% unchanged in urine; amiloride ~50% unchanged in urine. Minor biliary/fecal elimination (<10% for each).
Category C
Category C
Diuretic
Diuretic